EMERYVILLE, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Bionovo, Inc. announced today the appointment of Ethan Weiss, M.D., to the company’s Scientific Advisory Board. Dr. Weiss is a cardiologist with expertise in clotting and coagulation diseases, and is a leading researcher at the Cardiovascular Research Institute and the Division of Cardiology at the University of California, San Francisco (UCSF).
“We are very excited to have Ethan on the scientific advisory board as we are advancing our drugs,” said Isaac Cohen, O.M.D., Bionovo’s Chairman and CEO. He added, “Dr. Weiss’s research focuses on the mechanism of clotting activation by estrogens. His work is critical to the clotting safety elucidation of Bionovo’s estrogen receptor beta selective drugs.”
Dr. Weiss added, “Our results, so far, are very comforting. In early experiments we can see that in contrast to estrogen, MF101 has no effect on clotting. Therefore, MF101 will most likely be a safer alternative for the treatment of menopausal symptoms.”
Dr. Ethan Weiss joined the faculty at UCSF in 2003 as Assistant Professor of Medicine. Dr. Weiss earned his medical degree from the Johns Hopkins University School of Medicine, and he completed his internship and residency at the John Hopkins Hospital. Dr. Weiss came to the University of California, San Francisco in 1998 as a cardiology fellow where he spent three years under the scientific mentorship of Dr. Shaun Coughlin in the Cardiovascular Research Institute studying the effects of thrombin signaling in platelets. He then completed his clinical fellowship and served as Chief Cardiology Fellow in 2002. Dr Weiss’ clinical focus includes acute care cardiology, coronary artery disease and general cardiology with special interests in thrombosis, preventive cardiology, and acute coronary syndromes. Dr. Weiss’ laboratory uses forward genetic models to enhance the understanding of mechanisms of hemostasis and thrombosis. In addition, his group is working to understand mechanisms of sex differences in blood clotting and to define the mechanisms whereby estrogen increases the risk of clotting.
Bionovo, Inc.
Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women’s health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, “BNVI”. For more information about Bionovo and its programs, visit: http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
CONTACT: Tom Chesterman or Claire Fong, both For Bionovo, +1-510-601-2000,
investor@bionovo.com
Web site: http://www.bionovo.com/
